



HIMSS Davies Enterprise Award

Case Study - Empowering Providers With Data to Affect Behavior and Reduce Percutaneous Coronary Intervention (PCI) Costs

UNC Health Care

Leveraging IT to Improve Patient Outcomes

September 11, 2018



Empowering Providers With Data to Affect Behavior and Reduce PCI Costs

Lauren Onken, MHA

Executive Director, UNCHCS Heart & Vascular

Joel Schneider, MD, FACC

Interventional Cardiologist, UNC REX

Joseph Rossi, MD, MSCI, FACC, FSCAI

Interventional Cardiologist, UNC Medical Center

Shaun McDonald

ISD Enterprise Architect

UNC Health Care System Overview

Providing care to patients in North Carolina

Who we are, Who we serve (1 of 3)

UNC Health Care System Overview

Integrated, not-for-profit health care system, owned by the State of North Carolina and based in Chapel Hill. We provide comprehensive patient care, facilitate physician education and research excellence, and promote the health and well-being of all North Carolinians




<u>Key Stats</u>	<u>2011</u>	<u>2017</u>
Net patient revenues	\$2.0B	\$4.9B
Licensed beds	1,530	>3,400
Employees	14,000	>31,500
Medical staff	3,186	>5,400
Employed MDs	2,110	>3,200
Surgeries	60,000	>120,000
ED visits	151,000	>510,000
Clinic visits	1.1M	>3.5M

We are committed to providing them high quality care across our state

Who we are, Who we serve (2 of 3)

Delivering High Quality Care Across the State



As a system, a success for one is a success for all

Who we are, Who we serve (3 of 3)



2016 HOSPITAL RANKINGS:
 8 nationally recognized adult specialties
 2 high performing adult specialties
 7 nationally recognized children's specialties

"BEST HOSPITALS IN THE REGION":
 UNC Hospitals
 UNC Rex
 High Point Regional

2016 SCHOOL RANKINGS
 #2 for Primary Care
 #2 School of Public Health

Local Problem

Across the nation pharmaceutical costs are rising – this is impacting patient care

Local Problem (1 of 4)

Background and Importance (Continued)



Rising pharmaceutical costs threaten patient access to drug therapies, but also challenge providers' ability to deliver value-based care to their patients

The American Hospital Association (AHA) and the Federation of American Hospitals (FAH) commissioned a study at the University of Chicago in 2016 to better understand how drug prices are changing in the inpatient hospital setting [1]

Key Findings From This Study:



Increase in annual inpatient drug spending from FY13 - FY15 (5.2 to 6.5M)



Of hospitals reported that inpatient drug prices increases had a moderate or severe effect on their ability to manage costs

Case Study: Percutaneous Coronary Intervention (PCI)


Local Problem (2 of 4)

Patient: 57 year old male presents to ER with crushing chest pains

Exam: Diaphoretic and Restless BP 90/69 HR 110

EKG: ST elevation anterior leads

DX: STEMI (acute heart attack)



Choosing Bivalirudin for PCI is 300 times more expensive than Heparin

Local Problem (3 of 4)

Background and Importance



In 2008, the *New England Journal of Medicine* “HORIZONS-AMI” study suggested that bivalirudin decreased bleeding and possibly improved survival with AMI patients requiring PCI [2]. As a result, from 2008-2013 there was a nationwide increase in bivalirudin use for all PCI.

2008 - 2014, two things happened that changed Angiomax usage: (1) Transradial PCI becomes more widespread reducing bleeding risk & (2) Sporadic cases of stent thrombosis with Bivalirudin reported in the literature

In 2014, a subsequent study, “HEAT-PPCI” challenged using bivalirudin suggesting heparin strategy reduced the incidence of major adverse ischaemic events with no increase in bleeding complications [3].

The study showed bivalirudin was about 300 times more expensive than heparin. It was estimated that switching to heparin would reduce the cost of their annual 1000 PPCI cases by £500 000, ~ \$640,000 (US dollars)

Today's focus


Despite the new information from the “HEAT-PPCI” study and our own cost data, many physicians were reluctant to stop using the bivalirudin.

At UNC MC and UNC REX, Bivalirudin was the primary anticoagulant used for PCIs

Local Problem (3 of 3)

Baseline – Percentage of PCI Cases using Bivalirudin – By Hospital

PCI Cases Using Bivalirudin was 88.24% (UNC Medical Center) and 77.47% (UNC REX).




At 300 times the Cost of Heparin + High Utilization = High Costs w/ Questionable Value

Design and Implementation

Our journey, from a heparin-first pilot to the creation of a dashboard to drive change

Design and Implementation (1 of 7)

Overview



A committee was formed with multiple subject matter experts (SMEs)

Design and Implementation (2 of 7)

Governance Committee

Core Multidisciplinary Committee (e.g. Physician and Operational Leaders, Analysts, etc.)


Initial work identified opportunities to:

- 1) Standardize best practices
- 2) Improve quality
- 3) Reduce direct costs, improve current contribution margin, and position UNCHCS for bundle payment success
- 4) Improve operational efficiency and throughput

Selected opportunities included:


- ✓ 1) *Reduce use of bivalirudin & substitute heparin*
- 2) Utilize lower cost routine supplies
- 3) Reduce variation in supply usage

Structure and Focus



This project was well-suited for the DMAIC methodology

Design and Implementation (3 of 7)



To create our PCI dashboard, we used our standard development process/approach

Design and Implementation (4 of 7)



- Create a system-wide solution

- Centralize key metrics pulled from multiple systems

- Create a shared understanding of performance and opportunities

- Near real-time data so progress and initiatives can be regularly monitored

- Opportunities should be easily identifiable and visible

- Source systems identified, data mapped to data model, and ETL to move the data into our data warehouse

- Reporting layer created within BI tool to simplify reporting efforts

- Metric logic built into objects to pre-calculate values

- Results are validated against data submissions to national registries

- Source system validation to ensure data matches what is shown

- Metric calculation documentation created

- Made dashboard accessible to executive and analysts supporting these departments


- Providers review their own data to understand performance and opportunities

After gathering initial requirements, we married disparate data sources

Design and Implementation (5 of 7)

To gain a comprehensive view of our PCI events, we married data elements stored across multiple databases

Integrating Data Into the Data Warehouse



Data Elements

Carolina Data Warehouse for Health

- Enterprise Data Warehouse contains a data mart with cardiac data curated for analytics

Lawson (Supplies)

- Item number, Manufacturer, Last purchase price

RxWorks (Pharmacy)

- NDC code, Lot number, Last purchase price


Apollo and Merge (Cardiology Systems)

- Supply usage/waste, event timestamps, interventionalists, patient encounter information


Next we created a few mock-ups, eventually landing on our final dashboard design

Design and Implementation (6 of 7)

Original Dashboard Mock-Ups



Actual PCI Dashboard



The goal of this dashboard was to “change behavior”

Design and Implementation (7 of 7)

Intended Goals and Outcomes



Primary Goal: To understand and share the ordering practice patterns and behaviors to help shift the mindset of our providers

Educate providers about the cost of drugs

Demonstrate maintained or improved outcomes as a result of the switch from bivalirudin to heparin

Minimize case-complexity and population differences by using statistical clustering

Educate providers about their peer’s usage



Leveraging Health IT

Using the PCI dashboard - Functionality

How Health IT Was Utilized (1 of 4)

Provides end-users with a flexible interface to review and compare trends for ongoing improvement and monitoring

Input Controls


Change chart types and filters to drill into data and find opportunities

Comparison

Review results by cath lab location, provider, date ranges, etc.

Standardized Data

Data from multiple system is normalized and loaded into a single source for common reporting to occur



Filters Currently Applied

Summary of filters applied shows on the report

Bivalirudin Usage


Key metrics are posted on the front page of the dashboard for ongoing monitoring

Using the PCI dashboard - Volume & Utilization Measures

How Health IT Was Utilized (2 of 4)

Multiple graphs show PCI volume, procedure mix, bivalirudin usage, supply costs, rehab referrals, etc.

- 1 PCI Volume
- 2 Average Supply Cost Per PCI
- 3 PCI Procedure Mix
- 4 Cardiac Rehabilitation
- 5 Discharge Medication in Eligible Patients
- 6 Bivalirudin Use



Using the PCI dashboard – Quality Measures

How Health IT Was Utilized (3 of 4)


The dashboard includes trends in key PCI quality data (e.g., mortality, bleeding events, vascular complications, etc.) to identify any significant increase in complications

1 Median Contrast Dose (NCDR 1648)

2 Unadjusted Mortality Rate

3 Bleeding Events Within 72 Hours of PCI

4 Unadjusted Vascular Complication



Providing accurate and meaningful data can change physician behavior

How Health IT Was Utilized (4 of 4)

Sharing Data With Colleagues

The dashboard was shared at many meetings and other forums to maximize awareness

Physicians received un-blinded dashboards and had access to their colleagues information, while staff received blinded dashboards

✓ Overall, it was very well received by physicians and cath lab staff



*The **cardiologists** received the information in an extremely positive fashion. After training, most doctors and us interventional cardiologists work independently during cases and patient care with limited exposure to our partners. **Being able to share practice patterns and understand cost/quality among peers resulted in positive change in behavior.***

- Dr. Joel Schneider, UNC REX Physician Champion


Value Derived

Significant reduction in the percentage of PCI cases using Bivalirudin

Value Derived (1 of 7)

Bivalirudin usage declined significantly during this initiative and has consistently remained very low


There's been a 90% percent reduction in Bivalirudin usage since the start of this effort



The dashboard played a key role in supporting education and adoption efforts

Value Derived (2 of 7)

Bivalirudin usage declined significantly during this initiative and has consistently remained very low



This reduction represents a total savings of ~\$1.6 million annually

Value Derived (3 of 7)

The savings amount is calculated as the cost difference between Heparin and Bivalirudin per administration multiplied by the number of cases

ROI – Savings for CY17


Item	Amount
Additional Hardware Infrastructure Required	+ \$0
Heparin Medication Cost Per Administration	+ \$4.68
Bivalirudin Medication Savings Per Administration	- \$727.65
Total Savings from Education in CY17 (284 cases during CY17 – Providers on previous slide)	- \$ 176K
Total Savings from overall initiative in CY17 (2,886 cases during CY17)	- \$ 1.6 Million

Most importantly, this substitution has not impacted patient quality or safety (1 of 3)

Value Derived (4 of 7)

Adverse events and vascular complications are the primary measures monitored to ensure that anticoagulation medications are working correctly and preventing harm

Risk adjusted bleeding events




Most importantly, this substitution has not impacted patient quality or safety (2 of 3)

Value Derived (5 of 7)

Adverse events and vascular complications are the primary measures monitored to ensure that anticoagulation medications are working correctly and preventing harm

In-Stent Thrombosis (%)




Most importantly, this substitution has not impacted patient quality or safety (3 of 3)

Value Derived (6 of 7)

Adverse events and vascular complications are the primary measures monitored to ensure that anticoagulation medications are working correctly and preventing harm

Observed vs Expected Mortality Ratio



It was done without the need to add additional disruptive alerts to the system

Value Derived (7 of 7)

Overwhelming physicians with additional disruptive prompts that could increase to alert fatigue and lead to patient safety events [1]

UNC has taken an education-first approach to change influence provider behavior

Un-blinding data and showing individual provider's performance against their peers has proven effective for many of our quality and utilization initiatives for several reasons:

- **They may not be aware of the process or don't otherwise know the numbers**
I didn't realize practice recommendations had changed for bivalirudin usage
- **Drives information sharing about best practices between providers**
How is your average price per stent so low, what product are you using?
- **Providers are competitive**
I have to make sure my patient gets their discharge meds so that I can beat Dr X this month!

This method works best when providers know that leadership is also reviewing the same data at regular meetings

Intrusive provider alerts are only used as a means of last resort or when the prevention of adverse events warrants such an interruption

Next Steps

Next Steps

Continuous Improvement

- 1 The PCI dashboard allows continued monitoring for adverse events as well as other supply cost opportunities for savings and standardization**
- 2 The translational model of moving positive findings from one institution (UNCCMC) to another (UNC REX) by leveraging comparative can lead to other value-added opportunities at other hospitals across the health care system**
- 3 Analyzing and sharing practice patterns through the dashboard can identify new opportunities and influence individual physicians to adopt best practices**
- 4 Scale this concept to other procedures and entities in cardiology such as AICD implantation, STEMI management, stress testing, etc.**

Questions